Cargando…
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
Hepatocellular cancer (HCC) is a very fatal disease due to limited therapeutic options as well as due to its association with underlying chronic liver disease in the majority of cases. The immune evasion in HCC signifies a major barrier to the delivery of effective immunotherapy. Sorafenib is the on...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308591/ https://www.ncbi.nlm.nih.gov/pubmed/28223846 http://dx.doi.org/10.2147/CMAR.S111673 |